↓ Read PDF
01 · ABSTRACT

Abstract

Early-stage life science ventures operate under conditions of extreme biological, regulatory, and economic uncertainty. They routinely struggle to communicate decision readiness to investors and industry partners because conventional pitch decks and business plans emphasize narrative ambition, market size, and long-term upside while under-specifying scientific risk, regulatory uncertainty, and staged decision logic. Research in translational medicine, venture governance, real options theory, and stage-gate innovation governance shows that investors and organizations allocate early-stage capital to resolve dominant uncertainties through incremental, sequential learning, tying continuation decisions to predefined technical and commercial criteria rather than to persuasive vision alone. Despite this logic, early-stage pitching practices rarely operationalize explicit continuation, narrowing/redesign, or termination thresholds within their artifact design.

This paper conceptually examines early-stage pitch and planning artifacts as decision-support mechanisms under conditions of extreme biological and regulatory uncertainty. They exist as pre-contractual governance mechanisms that simulate stage-gate discipline upstream of formal portfolio review systems. Drawing on illustrative preclinical exemplars in the drug, device, drug-delivery, gene therapy, and platform domains, the analysis identifies recurring structural misalignments in scientific pitching. These include risk stacking across platform feasibility and downstream scope before anchor validation, premature commercialization framing, narrative rather than decision-relevant milestones, and the absence of explicit, predefined gate thresholds that link capital deployment to uncertainty resolution. These design failures obscure governing uncertainties, increase perceived risk, and reduce evaluability even when the underlying science is strong.

To address this gap, this work introduces an investability framework that organizes early-stage evaluation around four decision domains: problem reality, solution differentiation, de-risking path, and value capture logic. It also presents a milestone-driven, 12-slide pitching roadmap that operationalizes staged capital discipline. The framework reframes the pitch deck from persuasive narration into a governance instrument that clarifies uncertainty prioritization, learning velocity, and continuation thresholds. By translating stage-gate logic into upstream artifact design, the framework reframes pitching as a governance exercise that structures staged commitment before formal control rights exist. Rather than promising higher success rates in an inherently high-attrition domain, the model improves decision clarity, reduces governance ambiguity, and strengthens disciplined allocation of scarce translational capital. Thus, it aligns early-stage communication with the institutional capital allocation norms that govern later-stage innovation systems.

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 14 No 3 (2026): Vol.14, Issue 3, March 2026
SectionResearch Articles
Published26 March 2026
DOI10.18103/mra.v14i3.7292
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 4.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

JY

John M. York

The Institute for the Global Entrepreneur at the Jacobs School of Engineering and the Sullivan Center at the Rady School of Management, University of California, San Diego (United States of America),

ORCID
Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗